These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6334141)

  • 1. Systemic administration of recombinant human interleukin-2 in mice.
    Chang AE; Hyatt CL; Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):561-72. PubMed ID: 6334141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
    Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
    Gately MK; Anderson TD; Hayes TJ
    J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of recombinant human interleukin-2 in rats following intravenous infusion.
    Matory YL; Chang AE; Lipford EH; Braziel R; Hyatt CL; McDonald HD; Rosenberg SA
    J Biol Response Mod; 1985 Aug; 4(4):377-90. PubMed ID: 3875693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motility and tumoricidal activity of interleukin-2-stimulated lymphocytes.
    Ratner S; Heppner GH
    Cancer Res; 1988 Jun; 48(12):3374-80. PubMed ID: 2453269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of guinea-pig immune functions by interleukin 2: critical role of natural killer activity in acute HSV-2 genital infection.
    Weinberg A; Basham TY; Merigan TC
    J Immunol; 1986 Nov; 137(10):3310-7. PubMed ID: 3021853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of liver lymphoid cell subsets pre- and post-in vivo administration of human recombinant interleukin 2 in a C57BL/6 murine system.
    Lafreniere R; Borkenhagen K; Bryant LD; Anton AR; Chung A; Poon MC
    Cancer Res; 1990 Mar; 50(5):1658-66. PubMed ID: 2302721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of natural killer cell numbers but not function in leukemic infant mice: a system primed in infancy allows survival in adulthood.
    Dussault I; Miller SC
    Nat Immun; 1993; 12(2):66-78. PubMed ID: 8318817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
    Wiltrout RH; Boyd MR; Back TC; Salup RR; Arthur JA; Hornung RL
    J Immunol; 1988 May; 140(9):3261-5. PubMed ID: 3258894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes.
    Mazumder A; Rosenstein M; Rosenberg SA
    Cancer Res; 1983 Dec; 43(12 Pt 1):5729-34. PubMed ID: 6640524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.